Zavodovsky B V, Sivordova L E, Polyakova Yu V, Akhverdyan Yu R, Kuznetsova M I, Zborovskaya I A
Research Institute of Clinical and Experimental Rheumatology, Volgograd, Russia.
Ter Arkh. 2016;88(12):78-81. doi: 10.17116/terarkh2016881278-81.
To evaluate the clinical efficacy and tolerability of etoricoxib and meloxicam in patients with gonarthrosis.
A postregistration, open-labeled, prospective, comparative randomized study was conducted. 40 patients aged 37 to 75 years with primary knee osteoarthritis were examined. Therapeutic effectiveness was evaluated determining the functional index WOMAC with the use of a visual analogue scale (VAS). The tolerability of the drugs was assessed according to the opinions of a patient and a physician.
Both drugs caused a reduction in WOMAC and VAS scores for pain and the severity of the disease. Etoricoxib demonstrated a significantly high rate of occurrence and completeness of its analgesic effect. Meloxicam showed a less pronounced decrease in joint stiffness and an insufficient analgesic effect. The incidence of side effects was similar in both groups.
Both drugs demonstrated a good tolerability and a low incidence of side effects. The efficacy of etoricoxib was significantly higher than that of meloxicam.
评估依托考昔和美洛昔康治疗膝骨关节炎患者的临床疗效和耐受性。
进行了一项注册后、开放标签、前瞻性、比较随机研究。检查了40例年龄在37至75岁的原发性膝骨关节炎患者。通过使用视觉模拟量表（VAS）测定功能指数WOMAC来评估治疗效果。根据患者和医生的意见评估药物的耐受性。
两种药物均使WOMAC和VAS疼痛评分及疾病严重程度降低。依托考昔显示出显著高的镇痛效果发生率和完整性。美洛昔康在关节僵硬方面的降低不太明显，镇痛效果不足。两组的副作用发生率相似。
两种药物均显示出良好的耐受性和低副作用发生率。依托考昔的疗效显著高于美洛昔康。
